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Background: Increased visceral fat and pancreatic steatosis promote lymphatic metastases and
decreased survival in patients with pancreatic adenocarcinoma after pancreatoduodenectomy (PD).
Objectives: We aim to determine the utility of preoperative computed tomography (CT) measure-
ments of pancreatic steatosis and visceral fat as prognostic indicators in patients with pancreatic
adenocarcinoma.
Methods: High-resolution CT scans of 42 patients undergoing PD for pancreatic adenocarcinoma were
reviewed. Attenuation in CT of the pancreas, liver and spleen were measured in Hounsfield units and
scored by two blinded investigators. Perirenal adipose tissue was measured in mm.
Results: Lymphatic metastases were present in 57% of patients. Age, gender, tumour size and margin
status were similar in patients with and without nodal metastases. Node-positive patients had increased
visceral but not subcutaneous fat pads compared with node-negative patients and decreased CT
attenuation of the pancreatic body and tail and liver. Node-positive patients stratified by visceral adiposity
(10 mm vs. <10 mm) demonstrated poorer survival (7  1 months vs. 16  2 months; P < 0.01).
Conclusions: In resected pancreatic adenocarcinoma, increased pancreatic steatosis and increased
visceral fat stores are associated with lymphatic metastases. Furthermore, increased visceral fat is
associated with abbreviated survival in patients with lymphatic metastases. Hence, increased visceral fat
may be a causative factor of abbreviated survival and serves a prognostic role in patients with pancreatic
malignancies.
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Introduction
Nearly 1.1 billion people worldwide and over a third of the Ameri-
can population are estimated to be overweight.1,2 Further, obesity
has been associated with increased risk for the development of
multiple cancers.3,4 In 2003, the International Agency for Research
on Cancer identified a causal link between obesity and increased
risk for colon, breast, endometrial, renal cell, oesophageal, liver
and pancreatic cancer.3,4 More recently, evidence supporting this
epidemiological relationship has been strengthened with the
identification of an altered adipokine milieu in obese patients.
For example, levels of serum leptin (a pro-angiogenic, pro-
tumorigenic adipokine) are elevated in obesity, whereas serum
levels of adiponectin (an anti-tumorigenic adipokine) are
decreased.5–9 Furthermore, adipokine receptors have been demon-
strated on numerous cancer cells, including in pancreatic adeno-
carcinoma, which lends mechanistic support to the association of
obesity with increased risk for cancer.
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Pancreatic cancer has become the fourth leading cause of
cancer-related death in the USA and is associated with the shortest
stage-for-stagemedian survival time of all cancer types.10,11 Higher
body mass index (BMI) has been shown to increase the relative
risk for development of pancreatic cancer.10–14 Importantly, pat-
terns of fat distribution resulting in central adiposity have been
shown to represent an independent risk factor in the development
of pancreatic cancer.15 Moreover, recent data have shown histo-
logically increased intrapancreatic fat correlates with lymphatic
spread and decreased survival in patients undergoing pancre-
atoduodenectomy (PD) for pancreatic cancer.16 However, a corre-
lation between preoperative adipose measurements assessed by
computed tomography (CT) and patient outcomes remains ill
defined. Therefore, this study was undertaken to evaluate whether
visceral fat and pancreatic steatosis measured by preoperative CT
are predictors of nodal metastases and survival after PD for pan-
creatic adenocarcinoma.Our hypothesis in undertaking this study
was that increased visceral fat and pancreatic steatosis would
promote nodal metastases and reduced survival after PD for pan-
creatic adenocarcinoma.
Materials and methods
Approval to conduct this study was obtained from the University
of South Florida Independent Research Board. Forty-two patients
in whom high-quality, triple-phase CT imaging studies had been
taken between January 2002 and December 2008 were identified
from our prospectively maintained database. Sample size was
limited as a large number of referred patients bring with them CT
images obtained at outside diagnostic centres and these cannot
be uploaded to obtain the CT measurements described in the
methods below. All patients had tumours in the head of the pan-
creas and underwent pylorus-sparing PD with curative intent.
Operative time was measured from the induction of general ana-
esthesia until discharge from the operating room. Clinicopatho-
logical data were extracted and correlated with CT findings. For
the purposes of comparison, patients were grouped according to
nodal status (N1 vs. N0; American Joint Committee on Cancer
[AJCC] criteria, 6th edition).17 Hospital length of stay (LoS)
included preoperative hospital days, which were often numerous,
reflecting transfers into our hospital. Pancreatic fistulas were cat-
egorized according to the International Study Group of Pancreatic
Fistula (ISPGF) classification.18
To the best of our knowledge, all patients reported in this study
received adjuvant therapy and completed a course of gemcitabine-
based chemotherapy. Our tertiary referral centre treats patients
from across the state of Florida and a large majority of patients
ultimately receive adjuvant chemotherapy administered by their
local medical oncologist for convenience.
CT analysis
All CT imaging was evaluated in the non-contrast phase by two
blinded radiologists. Fatty infiltration (i.e. steatosis) of the pan-
creas, liver and spleen was assessed by attenuation, which was
measured in Hounsfield units (HU). Attenuation in CT was indi-
vidually measured in the head, body and tail of the pancreas; CT
attenuation in the liver was averaged over three measurements
taken in the right, left and caudate lobes of the liver, respectively.
Subcutaneous fat thickness was recorded in mm as the distance
between the iliac plate and skin at the level of the posterior superior
iliac spine. As an indicator of visceral obesity, the perirenal fat pad
was measured in mm as the vertical distance between the left
posterior renal capsule and the junction of the abdominal wall and
paraspinal musculature at the level of the left renal vein (Fig. 1).
Statistical analysis
Statistical analyses were performed using SigmaStat 3.5 (Jandel
Corp., San Jose, CA,USA).Data are expressed as mean standard
deviation (SD). Data that were >2 SD from the mean were deter-
mined for each subgroup analysis and excluded from that statis-
tical analysis. Data were analysed using Student’s t-test and
N0                 N1(B)(A)
Figure 1 Typical computed tomography scans in (A) a node-negative (N0) and (B) a node-positive (N1) patient. The N0 patient has essentially
no visceral fat pad, but the N1 patient has an approximately 3-cm fat pad
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Fisher’s exact test, where appropriate. Survival analyses were per-
formed using Kaplan–Meyer methods. Significance was accepted
with 95% confidence.
Results
Patient demographic data are depicted in Table 1, stratified by
nodal status. Average patient age was 46 years 11, Twenty three
patients were men. All patients were overweight (i.e. BMI > 25 kg/
m2). Data from the pathology evaluation are depicted in Tables 2
and 3 stratified by nodal status. No in-hospital mortality was
noted in the study cohort. Operative time (320 60 min and 382
 70 min), estimated blood loss (EBL) (560  120 cc and 620 
130 cc) and hospital LoS (15  3 days and 18  2 days) were
similar for patients without and with lymph node metastases,
respectively. Additionally, no differences were found between
patients with perirenal fat pads measuring 10 mm and those
with perirenal fat pads of <10 mm in operative time (340 
60 min and 360  80 min, respectively), EBL (570  110 cc and
630  140 cc, respectively) and hospital LoS (18  4 days and 16
 5 days, respectively). Fistula rates (33% and 36%) were similar
in patients without and with lymph node metastases, respectively.
All six of the fistulas in patients with node-negative disease were
Grade A. Seven of the eight fistulas in node-positive patients were
Grade A and one was Grade B.Overall survival in patients without
and with lymph node metastases was 21 10 months and 11 7
months, respectively (P < 0.01).
Data from CT analyses are depicted in Table 3. Attenuation in
CT of the pancreatic body (35 15 HU and 23 9 HU; P < 0.01)
and pancreatic tail (34  15 HU and 21  8 HU; P < 0.01) were
significantly different in patients without and with lymph
node metastases, respectively. By contrast, CT attenuation of
the pancreatic head (33  15 HU and 28  10 HU) and spleen
(48 15 HU and 44 7 HU) did not significantly differ between
patients without and with lymph node metastases, respectively.
Attenuation in CT of the liver (50  8 HU and 58  14 HU;
P < 0.01) differed significantly between patients with and
without lymph nodemetastases, respectively.Attenuation in CT of
the pancreas (mean HU) and liver are depicted in Figure 2, strati-
fied by nodal metastases. Subcutaneous fat pads were
similar (21  13 mm and 18  9 mm; P = not significant
[NS]) in patients with andwithout lymphnodemetastases, respec-
tively, although visceral obesity (i.e. perirenal fat) was significantly
increased in patients with lymph node metastases compared with
patients without lymph node metastases (18  5 mm and 13 
7 mm, respectively; P < 0.01) (Fig. 3). Additionally, the percentage
of patients with peripancreatic fat invasion was significantly
greater in the group with lymph node metastases than in that
without (90% and 53%, respectively; P < 0.01) (Fig. 3). Patients
with known lymph node metastases were stratified subsequently
according to perirenal fat measurements (<10 mm vs.10 mm).
Twelve patients had <10 mm of perirenal fat (9  4 mm) and 12
patients had10 mm of perirenal fat (21 5 mm).
Table 1 Patient demographic data
N0 N1
Patients, n 18 24
Age, years 67  11 66  10
Male gender 61% 50%
Metabolic syndrome
Body mass index, kg/m2 27  4 28  6
Hypertension 44% 46%
Hyperlipidaemia 33% 33%
Diabetes 39% 21%
N0, node-negative; N1, node-positive
Table 2 Histopathological parameters
N0 N1
Tumour size, cm 3.4  2.34 3.6  1.12
Perineural invasion 67% 71%
Angiovascular invasion 27% 29%
Poor differentiation 12% 52%a
Peripancreatic fat invasion 53% 90%a
R0 resection 100% 69%
aP < 0.01 vs. N0
N0, node-negative; N1, node-positive
Table 3 Comparison of adiposity and survival in patients without and with lymph node metastases stratified by visceral fat
Lymphatic
invasion
Subcutaneous
fat pad, mm,
mean  SD
Perirenal fat
pad, mm,
mean  SD
Pancreatic
head, HU,
mean  SD
Pancreatic
body, HU,
mean  SD
Pancreatic
tail, HU,
mean  SD
Liver, HU,
mean  SD
Spleen, HU,
mean  SD
Survival,
months,
mean  SD
N0 18  9 13  7 33  15 35  15 34  15 58  14 48  15 21  10
N1 21  13 18  5a 28  10 23  9a 21  8a 50  8a 44  7 11  7a
N1 + fat
pad < 10 mm
20  11 9  4 26  7 27  7 27  8 53  7 48  7 16  6
N1 + fat
pad  10 mm
20  13 21  5b 25  8 25  12 20  12 48  8 46  5 7  3b
aP < 0.01 vs. N0
bP < 0.01 vs. N1 and fat pad < 10 mm
N0, node-negative; N1, node-positive
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Overall survival was significantly shorter in patients with lymph
node metastases and perirenal fat10 mm (7 3 months) com-
pared with patients with lymph node metastases and perirenal fat
of < 10 mm (16 6 months) (P < 0.01) despite similar pancreatic
CT attenuation measurements (Figs 4, 5, Table 3). No differences
in survival were noted between patients with perirenal fat of
10 mm (n = 30; 12  14 months) and those with perirenal fat
of <10 mm (n = 12; 16  12 months) (P = 0.3). Similarly, no
differences were noted in the percentage of patients with lymph
node metastases among patients with perirenal fat of 10 mm
and those with perirenal fat of <10 mm (50% and 58%, respec-
tively; P = 0.37).
No differences in survival were noted between patients with
lymph node metastases and pancreatic body CT attenuation of
30 HU (n = 9; 15  6 months) and patients with lymph
node metastases and pancreatic body CT attenuation of <30 HU
(n = 15; 10  7 months) (P = 0.08). No differences in survival
were noted between patients with pancreatic body CT attenua-
tion of 30 HU (n = 19; 18  11 months) and patients with
pancreatic body CT attenuation of <30 HU (n = 23; 16  15
months) (P = 0.7). However, a statistically greater percentage of
patients with a fatty pancreas (<30 HU vs.30 HU) had positive
lymph nodes (70% vs. 42%; P < 0.002).
The average BMI of all patients was 27  6 kg/m2. No
statistically significant correlation was noted between BMI and
visceral fat (R = 0.375, P = 0.4), BMI and subcutaneous fat
(R = 0.53, P = 0.08) or perirenal fat and subcutaneous fat
(R = 0.18, P = 0.7).
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Figure 2 Computed tomography attenuation in Hounsfield units
(HU) of the pancreatic body and liver. N0, node-negative patients;
N1, node-positive patients; aP < 0.01 vs. N0
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Figure 3 Perirenal adiposity in mm and percentage of patients with
peripancreatic fat invasion. N0, node-negative patients; N1, node-
positive patients; aP < 0.01 vs. N0
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Figure 4 Node-positive patients stratified by perirenal adiposity
in mm and computed tomography attenuation of the pancreatic
body in Hounsfield units (HU). N0, node-negative patients; N1,
node-positive patients; aP < 0.01 vs. N1 + fat pad of <10 mm
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Figure 5 Survival rates in node-positive patients with perirenal
adiposity of 10 mm (solid line) and <10 mm (broken line)
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Discussion
Outcomes for patients with pancreatic adenocarcinoma are
extremely poor for a myriad of reasons, including difficulties in
early detection, aggressive tumour biology with a propensity for
early systemic metastases, and the unavailability of efficacious
chemotherapeutic agents. Recently, the negative impact of obesity
on cancer-specific outcomes has been elucidated in pancreatic
adenocarcinoma, as well as in other malignancies, although
accurate preoperative identification of patients with clinically sig-
nificant changes in adiposity remains challenging. Computed
tomography has been recently validated as ameasure of evaluating
solid organ and intra-abdominal fat.19,20 Therefore, we chose to
use preoperative CT to measure visceral steatosis. We have dem-
onstrated a correlation between CT attenuation of the pancreas
and liver, as well as increased perirenal fat, and the development of
lymph node metastases. More importantly, we have documented
that organ steatosis as measured by CT attenuation portends poor
survival and that increased perirenal fat is an independent pre-
dictor of abbreviated survival in patients with lymph node
metastases, which suggests that the negative physiological impacts
of visceral adiposity can be inferred from routine radiographic
evaluations.
Our study population is representative of patients with pancre-
atic adenocarcinoma undergoing PD both at our institution and
around the country.21,22 The patients were generally older than
middle age and more than half were men. All patients in the study
population were overweight. Similarly, survival data for the study
population concur with survival data reported in other large-
institution studies.20,21 Unfortunately, our sample size was limited
by the availability of high-quality, triple-phase CT in our radio-
logical database. Our small sample size has made our statistics
vulnerable to type II error and this may account for the lack of
statistical significance with respect to increased pancreatic steato-
sis and survival.
Pancreatoduodenectomy represents the only chance for long-
term cure in pancreatic cancer. However, pancreatic cancer con-
tinues to remain a lethal disease with a mean 5-year survival of
<5% because most patients are not candidates for surgery.14,22
Recent epidemiological evidence has implicated obesity in the
development of and mortality from pancreatic cancer.13,14 In one
large-cohort study, Stolzenberg-Solomon et al. showed that
people with a BMI > 35 have a 45% greater risk for developing
pancreatic cancer.13 This association has been further strength-
ened by a recent meta-analysis which demonstrated that the rela-
tive risk for pancreatic cancer increases by 1.12 for every 5-point
increase in BMI.14 Moreover, Calle et al. have shown that mortality
from pancreatic cancer rises with increasing BMI.10
Fatty infiltration of the pancreas secondary to obesity was first
described by Ogilve in 1933.23 Multiple radiological studies have
validated this correlation between obesity and pancreatic fat.24
However, pancreatic steatosis is no longer believed to represent a
benign fallout of the obesity epidemic.Accumulating evidence has
now implicated pancreatic steatosis in the development of pan-
creatic pathology and morbidity from PD.16,25 This paradigm shift
is supported by this report and by a recent study demonstrating
that increased pancreatic steatosis correlates with increased lym-
phatic invasion, positive lymph nodes, and decreased survival
after PD.16 Our study provides further evidence of the deleterious
oncological outcomes of visceral steatosis by providing radiologi-
cal evidence that a statistically significant decrease in HU in the
pancreatic body, which corresponds to increased fatty infiltration,
is associated with a greater frequency of positive lymph nodes.
Moreover, the corollary is also true: patients with node-positive
disease have a more fatty pancreas. Interestingly, CT HU in the
pancreatic head did not differ between patients with node-
positive and node-negative disease. Differential distribution of fat
in the pancreas has been described anecdotally by radiological
imaging and may explain this finding. Another potential explana-
tion may lie in the fact that all the pancreatic cancers in this report
were located in the head of the pancreas and it is well known that
pancreatic cancer results in an intense desmoplastic response in
the surrounding tissue, which alters the texture of the peritumoral
gland.
The molecular mechanisms underlying the adverse impact of
pancreatic steatosis are likely to derive from an alteration of the
tumour microenvironment. Tumour–stroma interaction has been
established as playing a critical role in tumour proliferation and
metastases. Peritumoral inflammatory cell invasion and chemok-
ine expression patterns orchestrate these phenomena.26,27 Tissue-
associated macrophages and the subsequent production of
tumour necrosis factor (TNF), and interleukin-1 (IL-1) and IL-6
have been shown to stimulate angiogenic factors including
vascular endothelial growth factor (VEGF).26,27 Additionally,
macrophage-proinflammatory chemokine-3a (CCL) is overex-
pressed in peritumoral tissue in pancreatic cancer and stimulates
the growth of neoplastic cells in vitro.26,27 Animal data have
shown that obese mice have increased pancreatic fat content and
increased baseline levels of proinflammatory cytokines, including
TNF and IL-6.28 Moreover, TNF and CCL induce the production
of proteases and tumour-adhesion molecules that induce the
invasion and migration of tumour cells, thus promoting tumour
metastases.26 Our study supports this concept by showing that
elevated pancreatic steatosis is associated with lymph nodal
metastases.
Body mass index has historically been used as a surrogate
method for measuring an individual’s degree of obesity. Patients
with pancreatic cancer and a BMI > 35 have been shown to have a
12-fold increase in risk for nodal metastases and a two-fold
increase in risk for recurrence.29 However, BMI does not differen-
tiate among differing body fat distributions. Relative to subcuta-
neous fat, visceral fat has been established as the metabolically
active component of fat-producing adipocytokines. Central adi-
posity modulates the deranged production of cytokines, which
results in a systemic low-grade pro-tumorigenic, inflammatory
state. Thus, BMI represents, at best, a poor index for the deleteri-
408 HPB
HPB 2011, 13, 404–410 © 2011 International Hepato-Pancreato-Biliary Association
ous effects of obesity. We did not find any differences in BMI
between patients with and without nodal metastases. To further
elucidate the impact of the type of obesity, we measured both the
metabolically active component (visceral fat) and the inactive
component (subcutaneous fat). Visceral fat pad was increased by
38% in patients with nodal metastases. By stark contrast, no dif-
ference was noted in the subcutaneous fat pad in patients with and
without nodal metastases. Importantly, we did not find any sta-
tistically significant correlation between BMI and visceral fat, or
visceral fat and subcutaneous fat. These findings underscore the
importance of distinguishing the metabolically active component
of fat to provide greater sensitivity and relevance when examining
the effects of obesity on pancreatic pathology.
Multiple factors are known to influence prognosis following
PD, including age, tumour size, differentiation, resection margins
and lymph node status.30–32 We found no differences in our study
between node-positive and node-negative patients with respect to
age, tumour size and resection margins. The percentage of
patients with poor tumour differentiation was greater in node-
positive disease. This may be secondary to the pro-tumorigenic
environment provided by visceral and pancreatic steatosis. Impor-
tantly, a recent multivariate analysis identified lymph node status
as the only independent prognostic factor for longterm survival.32
Therefore, we further evaluated the survival of node-positive
patients after stratifying for a visceral fat pad of 10 mm. Dou-
bling the visceral fat in node-positive patients resulted in a dra-
matic 50% decrease in median survival. Interestingly, stratifying
the node-positive patients by pancreatic steatosis (pancreatic body
30 HU vs. < 30 HU) did not yield a statistically significant dif-
ference in survival, although there was a trend towards decreased
survival in patients with increased pancreatic steatosis. This may
represent a type II statistical error secondary to a small sample
size.
Intuitively, we would expect increased BMI and visceral adipos-
ity to result in a technically more difficult operation. However,
Fleming et al. have shown that surrogate measures of surgical
complexity such as EBL and operative time are not affected by
increased BMI.29 Our findings concur with these results in that no
differences in EBL or operative time were found in node-positive
patients with increased visceral adiposity.Moreover, there were no
differences in LoS and in-hospital mortality. This suggests that
visceral adiposity is not a deterrent to safe PD. However, studies
with larger sample sizes are needed to specifically address this
issue.
Since Kausch33 performed the first pancreatosuodenectomy,
mortality arising from the procedure has decreased to <5% at
most high-volume centres. However, morbidity continues to
range from 40% to 50%.30,31 Pancreatic fistula represents the most
important cause of morbidity. The risk factors identified for
fistula formation include a soft gland, small pancreatic duct,
underlying pathology, local blood flow and surgeon experi-
ence.34,35 Recent data have shown that increased pancreatic steato-
sis is an independent risk factor for fistula formation.36 The
reasons postulated are that a fatty gland would account for a
technically more difficult anastomosis and that elevated local
adipose tissue cytokines may result in a worsening of perianasto-
motic inflammation after surgical stress, which may enhance
fistula formation. In our study, node-positive patients had a more
fatty gland; however, although the fistula rate was increased in
node-positive vs. node-negative patients (36% vs. 33%), the dif-
ference was not statistically significant. This may be because our
study was not designed to evaluate fistula occurrence and was
underpowered to do so.
In summary, in resected pancreatic adenocarcinoma, increased
pancreatic steatosis and increased visceral fat stores are associated
with lymphatic metastases. Moreover, increased visceral fat is
associated with abbreviated survival in patients with lymphatic
metastases. Therefore, we conclude that visceral fat and pancreatic
steatosis play a role in disseminating cancer to lymph nodes (and
beyond) and that CT measurements of visceral fat predict the
dissemination and lethality of pancreatic adenocarcinoma.
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